NADAC acquisition cost data for ADDERALL 30 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
| 57844013001 | $8.56 | 2022-01-01 | Rx |
Generic: Dextroamphetamine/Amphetamine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $4.8M | 9,563 | 1,806 | $7.03 |
| 2020 | $5.3M | 10,244 | 1,609 | $7.50 |
| 2021 | $5.8M | 10,667 | 1,765 | $8.16 |
| 2022 | $7.1M | 12,017 | 2,201 | $9.11 |
| 2023 | $9.7M | 15,123 | 4,019 | $10.17 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Texas | $790.0K | 1,207 | 394 |
| California | $778.0K | 1,202 | 389 |
| New York | $725.0K | 1,052 | 244 |
| Florida | $591.8K | 879 | 223 |
| Massachusetts | $579.7K | 1,048 | 219 |
| Pennsylvania | $555.5K | 874 | 220 |
| Wisconsin | $498.3K | 824 | 244 |
| Michigan | $325.2K | 416 | 123 |
| New Jersey | $321.0K | 511 | 124 |
| Ohio | $282.0K | 445 | 119 |
| Connecticut | $270.9K | 410 | 110 |
| Arizona | $243.5K | 411 | 116 |
| Washington | $236.1K | 346 | 97 |
| Virginia | $235.5K | 315 | 109 |
| Minnesota | $235.0K | 430 | 96 |
| North Carolina | $219.7K | 328 | 102 |
| New Hampshire | $192.9K | 319 | 85 |
| Maine | $173.8K | 310 | 69 |
| Illinois | $172.4K | 250 | 81 |
| Indiana | $172.1K | 264 | 65 |
| Iowa | $155.4K | 260 | 56 |
| Maryland | $149.2K | 241 | 63 |
| Missouri | $141.7K | 230 | 56 |
| Colorado | $129.0K | 181 | 75 |
| Georgia | $124.2K | 205 | 62 |
| South Carolina | $89.8K | 131 | 26 |
| Oregon | $86.9K | 142 | 41 |
| Tennessee | $84.5K | 122 | 42 |
| Nebraska | $82.8K | 133 | 34 |
| Alabama | $82.7K | 130 | 47 |
| Kansas | $80.2K | 94 | 24 |
| Oklahoma | $77.9K | 137 | 40 |
| Kentucky | $77.6K | 115 | 50 |
| Louisiana | $76.1K | 123 | 39 |
| Rhode Island | $75.4K | 112 | 28 |
| Nevada | $65.3K | 116 | 26 |
| Utah | $62.4K | 101 | 29 |
| Vermont | $59.8K | 97 | 15 |
| Montana | $55.6K | 89 | 14 |
| Idaho | $44.7K | 96 | 27 |
| Hawaii | $42.3K | 52 | N/A |
| Arkansas | $40.8K | 57 | 14 |
| New Mexico | $37.7K | 65 | 14 |
| District of Columbia | $32.7K | 49 | 12 |
| West Virginia | $22.0K | 43 | N/A |
| Alaska | $20.0K | 24 | 16 |
| Mississippi | $17.5K | 33 | N/A |
| Delaware | $14.5K | 25 | N/A |
| South Dakota | $11.7K | 23 | N/A |
| North Dakota | $10.8K | 20 | N/A |
| Wyoming | $8.2K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.